AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05949060 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassion Intervention
Description: The compassion intervention is a single-session 40-min intervention in which the participants practiced soothing rhythm breathing (i.e., they are directed to slow their breathing using a five-count inhale and five-count exhale). They will then be provided didactic instruction on compassion, and will then be guided through an experiential compassion practice adapted that encompasses cultivating feelings of compassion for a loved one and then for oneself.
Study NCT06289257 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Vitamin D level
Description: Vitamin D level in blood
Study NCT06289257 — intervention group
Intervention type: OTHER
Intervention: Vitamin D receptor
Description: Vitamin D receptor in endometriosis tissue
Study NCT04910828 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Common foods of varying glycemic indices
Description: Examples of foods of varying glycemic index to be tested include bread, rice, breakfast cereals, starchy vegetables, legumes, fruit and dairy products.
Study NCT05877014 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaires
Description: EQ-5D-5L and SF-12
Study NCT05877014 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaires
Description: EQ-5D-5L and SF-12
Study NCT06345833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1%Tranexamic acid with standard local
Description: 1% TXA mixed with standard local consisting 1/4% lidocaine with 1:100,000 epinephrine with saline as the control.
Study NCT06345833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% TXA
Description: 3% TXA on TXA-soaked pledgets applied for 10 minutes with saline as the control.
Study NCT06345833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% TXA with local plus 3% TXA-soaked pledgets
Description: 1% TXA with local plus 3% TXA-soaked pledgets with saline as the control.
Study NCT05877014 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: scanner
Description: CT scan at M9 and then at M12 if the humerus is not consolidated at M6
Study NCT05877014 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scanner
Description: CT scan at M9 and then at M12 if the humerus is not consolidated at M6
Study NCT01343875 — intervention group
Intervention type: PROCEDURE
Intervention: tear of the distal tendon in the biceps muscle
Study NCT06446388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLS31905
Description: Administered as an intravenous infusion.
Study NCT06446388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m2, intravenous infusion, D1, up to 8 cycles.
Study NCT05570292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Domperidone
Description: ultrasound guieded assesment of gastric residual volume will be done 2 h after oral injestion of domperidone tablet
Study NCT05570292 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folic acid
Description: ultrasound guieded assesment of gastric residual volume will be done 2 h after oral injestion of folic acid tablet
Study NCT05457426 — intervention group
Intervention type: PROCEDURE
Intervention: robotic right hemicolectomy with CME
Description: The distribution of trocars was placed according to the position of Intuitive Surgical Inc. for robotic colectomy. The robot was set to come and dock from theright shoulder of the patient. Three robotic 8-mm trocars (R1, R2 and R3) and two 12-mm trocars (camera and assistant port) were used for the robotic procedure. One working arm carrying a monopolar cautery hook for dissection was located in the left upper quadrant port (R1). The other two working arms carried bipolar forceps in the suprapubic port (R3), and Cadiere's fenestrated forceps in the right lower quadrant port (R2) that was used to keep the superior mesenteric axis in traction. After gentle cephalad traction on the transversemesocolon with the grasp in R2, the assistant grasped the ileocecal valve through the assistant port to put the ileocolic vascular pedicle on tension and the ileocolic vessels were identified and lifted up with R3.
Study NCT06312267 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioelectric dressing
Description: Participants randomized into the experimental arm will have a bioelectric dressing applied 3 days before surgery, and 3 days post-surgery.
Study NCT04704999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tafenoquine
Description: Tafenoquine will be given as 100mg coated tablets. Tablets will be given based on weight bands.
Study NCT04704999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: Chloroquine will be given as daily dose over 3 days (25mg/kg total dose divided 10/10/5mg/kg)
Study NCT04884802 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tight pressure management
Description: Norepinephrine or phenylephrine infusion to maintain intraoperative MAP ≥85 mmHg.
Study NCT04884802 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Routine pressure management
Description: ACEIs, ARBs, and/or calcium channel blockers can be given the morning of surgery if deemed appropriate by the attending anesthesiologist. Intraoperative blood pressure will be managed per clinical routine.
Study NCT04722354 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperinsulemic euglycemic clamp
Description: Following a 12-hour overnight fast at the CRU (including abstinence from caffeine containing foods and beverages), insulin sensitivity will be measured using the criterion method of the euglycemic clamp. Participants will have not performed vigorous physical activity for at least the previous 24 h, and be free of acute illness for the prior 2 weeks. An intravenous catheter will be placed in an antecubital vein for subsequent insulin (40 mU/m2-min) and glucose infusions and for stable isotope (6, 6-2H2) infusions to measure insulin sensitivity.
Study NCT04722354 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hyperinsulemic euglycemic clamp
Description: Following a 12-hour overnight fast at the CRU (including abstinence from caffeine containing foods and beverages), insulin sensitivity will be measured using the criterion method of the euglycemic clamp. Participants will have not performed vigorous physical activity for at least the previous 24 h, and be free of acute illness for the prior 2 weeks. An intravenous catheter will be placed in an antecubital vein for subsequent insulin (40 mU/m2-min) and glucose infusions and for stable isotope (6, 6-2H2) infusions to measure insulin sensitivity.
Study NCT04722354 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Muscle Biopsy
Description: One biopsy taken prior to clamp and a second biopsy taken 30-45 min after the start of the clamp. A biopsy of the Vastus Lateralis muscle will be performed on the leg/thigh using the Bergstrom technique.
Study NCT04722354 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Muscle Biopsy
Description: One biopsy taken prior to clamp and a second biopsy taken 30-45 min after the start of the clamp. A biopsy of the Vastus Lateralis muscle will be performed on the leg/thigh using the Bergstrom technique.
Study NCT04722354 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral abscisic acid (ABA)
Description: Those in this group will receive ABA (95 µg ABA and 300 mg of corn starch)
Study NCT04722354 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Those in this group will receive placebo (300 mg cornstarch)
Study NCT06420700 — intervention group
Intervention type: PROCEDURE
Intervention: Combined gastric mucosal ablation with endoscopic sleeve gastroplasty
Description: Combined gastric mucosal ablation with endoscopic sleeve gastroplasty in the treatment of adults with obesity
Study NCT06535854 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prevail DCB
Description: The Prevail Paclitaxel-coated PTCA Balloon Catheter is intended for percutaneous transluminal coronary angioplasty (PTCA) in the coronary arteries with a vessel diameter from 2.00 mm to 4.00 mm to treat in-stent restenosis (ISR) and to treat de novo lesions in small vessel disease.
Study NCT06535854 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Agent DCB
Description: The Agent Paclitaxel-coated PTCA Balloon Catheter is intended for percutaneous transluminal coronary angioplasty (PTCA) in the coronary arteries with a vessel diameter from 2.00 mm to 4.00 mm to treat in-stent restenosis (ISR).
Study NCT05527769 — intervention group
Intervention type: PROCEDURE
Intervention: mastectomy + immediate breast reconstruction
Description: pre- or retro pectoral prosthesis
Study NCT04704999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether 20 mg-Lumefantrine 120 mg
Description: Artemether-lumefantrine will be given twice daily over 3 days. Whole tablets will be given based on weight bands.
Study NCT04846751 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TYPE OF EXERCISE (OR REST)
Description: continous exercise in normal temperature, continous exercise in hot environment, intervallic exercise in normal temperature.
Study NCT04846751 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: TYPE OF EXERCISE (OR REST)
Description: continous exercise in normal temperature, continous exercise in hot environment, intervallic exercise in normal temperature.
Study NCT05249231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride
Description: Previous studies have recommended silver diamine fluoride (SDF) to exert a preventive result in managing early childhood caries ECC. However, no well-designed clinical trials have yet been performed to study the effect of SDF on caries prevention. The result is useful in arresting early childhood caries (ECC)
Study NCT05249231 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hall technique
Description: The first report on the Hall Technique published in 2007 by a general dental practitioner from Aberdeen/Scotland, Dr. Norna Hall. Dr. Hall used PMCs to restore carious primary molars rather than using the standard technique, placed them using a simplified method
Study NCT06366932 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Second-line systemic treatment
Description: Patients with moderate to severe atopic dermatitis refractory to topical medication, who also have previous experience with cyclosporine and an unsatisfactory response, or in whom the use of cyclosporine is considered inappropriate due to contraindication or intolerance, are candidates for treatment with other alternatives (Dupilumab, Tralokinumab, Upadacitinib, Baricitinib, Abrocitinib).
Study NCT06366932 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Folllow-up of second-line systemic treatment already started
Description: If the patient is receiving second-line therapy at the moment of the inclusion, data will be collected from clinical records from treatment start until study inclusion and prospectively after study inclusion.
Study NCT05141591 — intervention group
Intervention type: OTHER
Intervention: Anxiety level assessment
Description: To investigate the impact of psychological variables e.g. pre-surgical anxiety on postoperative opioid consumption and pain level, the investigators will perform the STOA, APAIS, PCS and the VAS-A anxiety questionnaires before surgery.
Study NCT05477693 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental 23-valent PPV
Description: The investigational vaccine was manufactured by Sinovac Biotech Co., Ltd.25μg each for serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B,17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in 0.5 mL of sodium chloride, sodium dihydrogen phosphate and disodium hydrogen phosphate per injection.
Study NCT05913960 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham stimulation
Description: The parameters in the sham arm will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
Study NCT05477693 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Control 23-valent PPV
Description: The control vaccine was manufactured by Merck Sharp \& Dohme, Ltd. Purified capsular polysaccharides from 23 Streptococcus in 0.5 mL of pneumoniae types 0.25% phenol and sodium chloride.
Study NCT04877483 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture is a form of treatment that inserting very thin needles through a person's skin at specific points on the body. Group GB20 and Group GB20 plus BL2 will received the acupuncture treatment.
Study NCT05913960 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: accelerated intermittent theta burst stimulation
Description: Participants in the active stimulation group will receive the accelerated intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the neuronavigation system. Stimulation intensity will be standardized at 90% of RMT.~Stimulation will be delivered to the L-DLPFC using an NTK-TMS-II100 TMS device,is compatible with the Brainsight TMS navigation system.
Study NCT05913960 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high frequency stimulation
Description: Participants in the active stimulation group will receive the high frequnency stimulation to left DLPFC. The L-DLPFC will be targeted utilizing the neuronavigation system. Stimulation intensity will be standardized at 90% of RMT.~Stimulation will be delivered to the L-DLPFC using an NTK-TMS-II100 TMS device,is compatible with the Brainsight TMS navigation system.
Study NCT04421196 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exclusion of opioid analgesics
Description: The intervention involves removing the option of patients having an opioid analgesic at any time point during the perioperative period.
Study NCT04877483 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Oral microbiota
Description: Group GB20, Group GB20 plus BL2 and Healthy control will take the oral microbiota analysis.
Study NCT04877483 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Oral microbiota
Description: Group GB20, Group GB20 plus BL2 and Healthy control will take the oral microbiota analysis.
Study NCT04877483 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Schirmer's test
Description: Group GB20 and Group GB20 plus BL2 will take the Schirmer's test.
Study NCT04877483 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Schirmer's test
Description: Group GB20 and Group GB20 plus BL2 will take the Schirmer's test.
Study NCT04877483 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tear breakup time
Description: Group GB20 and Group GB20 plus BL2 will take the tear breakup time test.
Study NCT04738500 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PENG Block combinated with PCA
Description: After spinal anesthesia PENG block will be performed
Study NCT04738500 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: PCA
Description: PCA will be applied after surgery
Study NCT05577156 — intervention group
Intervention type: BEHAVIORAL
Intervention: Self-questionnaires and semi-structured interview
Description: Patients will fill these questionnaires : BISF-W, QLQ-C30, QLQ-BR23 and if they agree answer to a semi-structured interview composed of 5 questions
Study NCT06446388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 mg/m2, oral, bid, D1-D14
Study NCT06446388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 administered as IV infusion on D1/D8 of each cycle.
Study NCT06446388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25 mg/m2, intravenous infusion, D1/D8, up to 8 cycles.
Study NCT04877483 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Tear breakup time
Description: Group GB20 and Group GB20 plus BL2 will take the tear breakup time test.
Study NCT06446388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1706
Description: 5 mg/kg, intravenous infusion,D1
Study NCT04877483 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: OSDI(Ocular Surface Disease Index)
Description: Group GB20 and Group GB20 plus BL2 will take the OSDI test.
Study NCT04877483 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: OSDI(Ocular Surface Disease Index)
Description: Group GB20 and Group GB20 plus BL2 will take the OSDI test.
Study NCT04877483 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: TCM pattern
Description: Group GB20, Group GB20 plus BL2 and Healthy control will take the Traditional Chinese Medicine pattern diagnosis.
Study NCT04877483 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: TCM pattern
Description: Group GB20, Group GB20 plus BL2 and Healthy control will take the Traditional Chinese Medicine pattern diagnosis.
Study NCT04877483 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) tongue diagnosis
Description: Group GB20, Group GB20 plus BL2 and Healthy control will take the Traditional Chinese Medicine(TCM) tongue diagnosis.
Study NCT04877483 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Traditional Chinese Medicine (TCM) tongue diagnosis
Description: Group GB20, Group GB20 plus BL2 and Healthy control will take the Traditional Chinese Medicine(TCM) tongue diagnosis.
Study NCT04877483 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: TCM pulse diagnosis
Description: Group GB20, Group GB20 plus BL2 and Healthy control will take the Traditional Chinese Medicine(TCM) pulse diagnosis.
Study NCT04877483 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: TCM pulse diagnosis
Description: Group GB20, Group GB20 plus BL2 and Healthy control will take the Traditional Chinese Medicine(TCM) pulse diagnosis.
Study NCT04877483 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: TCM heart rate variability
Description: Group GB20, Group GB20 plus BL2 and Healthy control will take the TCM Heart rate variability.
Study NCT04877483 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: TCM heart rate variability
Description: Group GB20, Group GB20 plus BL2 and Healthy control will take the TCM Heart rate variability.
Study NCT04877483 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ESSPRI(EULAR Sjögren's Syndrome Patient Reported Index)
Description: Group GB20 and Group GB20 plus BL2 will take the ESSPRI.
Study NCT04877483 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ESSPRI(EULAR Sjögren's Syndrome Patient Reported Index)
Description: Group GB20 and Group GB20 plus BL2 will take the ESSPRI.
Study NCT04877483 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Whole-genome genotyping(TWBv2.0)
Description: Group GB20, Group GB20 plus BL2 and Healthy control will take the Whole-genome genotyping(TWBv2.0).
Study NCT04877483 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Whole-genome genotyping(TWBv2.0)
Description: Group GB20, Group GB20 plus BL2 and Healthy control will take the Whole-genome genotyping(TWBv2.0).
Study NCT04877483 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cytokine markers
Description: Group GB20, Group GB20 plus BL2 and Healthy control will take the cytokine markers(IL-17、MMP-9、BAFF、BCMA) analysis.
Study NCT04877483 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cytokine markers
Description: Group GB20, Group GB20 plus BL2 and Healthy control will take the cytokine markers(IL-17、MMP-9、BAFF、BCMA) analysis.
Study NCT04877483 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood biochemical analysis
Description: Group GB20 and Group GB20 plus BL2 will take the Blood biochemical analysis(BUN,Cre,AST,ALT,ESR and CRP).
Study NCT04877483 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood biochemical analysis
Description: Group GB20 and Group GB20 plus BL2 will take the Blood biochemical analysis(BUN,Cre,AST,ALT,ESR and CRP).
Study NCT06261450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD Oral Solution (eCBD system Target)
Description: Participants receive orally 6 ml of CBD Oral Solution (100 mg / ml; 60 mg / kg; max 600 mg of CBD) followed by 6 ml of a placebo composed of the inactive ingredients of CBD Oral Solution 3 weeks later.
Study NCT06261450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants receive orally 6 ml of a placebo composed of the inactive ingredients of CBD Oral Solution followed by 6 ml of Oral CBD Solution (100 mg / ml; 60 mg / kg; max 600 mg of CBD)
Study NCT04460573 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Boot
Description: Smart boot in one of three configurations provided to participants
Study NCT04460573 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Boot
Description: Smart boot in one of three configurations provided to participants
Study NCT06489860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIV
Description: Directions: For adults and for Children 1-12 years old. Indication: Anti-AIDS Drug. Ingredient: Organic Rice 91% and Honey 9% Powder (whole) 1g. Mix one packet with 6.8 fl oz (200 ml) of hot water (220ºF/100ºC) about three minutes until dissolved. Participants: Use 4 to 5 packets, use one pack each time after two hours.~Humidification: \<5%. Dosage Strength: 1.0 G/ 1 Unit, use one pack of 1 g for each time. Use within two years from the manufacturing date.